Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate

Bioresponsive reversible PEGylation: Altered distribution phenomena and associated pharmacodynamics differences of polymer conjugates compared to the wild type biologic remain challenges of PEGylated biologics. A bioinspired strategy of separation of insulin-like growth factor-I from PEG through disease-specific protease activity at the target site was able to regain the full pharmacological profile of the active protein.393